News|Video: Hi-Acts supports HZDR in launching the nukliD network for the cancer therapy of tomorrow
Video: Hi-Acts supports HZDR in launching the nukliD network for the cancer therapy of tomorrow
Dresden/ GermanyAugust 22, 2025
Radiopharmaceuticals are paving the way for a new era in oncology by offering therapies that precisely eradicate tumor cells while enabling real-time imaging to monitor treatment effectiveness. Recognizing this promise, the Hi‑Acts innovation platform, in close collaboration with the Helmholtz‑Zentrum Dresden‑Rossendorf (HZDR), has formally launched the nukliD network—a strategic initiative designed to strengthen ties between research, medicine, and industry, and to fast‑track these groundbreaking therapies from the lab into clinical practice.
Uniting Expertise for Effective Innovation
The nukliD network leverages the synergistic strengths of the Dresden region’s research institutions, clinics, and pharmaceutical partners. Its ambition is to create a seamless pathway for the development, testing, and large‑scale production of advanced radiopharmaceuticals. Hi-Acts and HZDR aim to foster an integrated ecosystem where scientific breakthroughs can be rapidly translated into real-world cancer treatments that are both precise and scalable.
Why nukliD Matters
Radiopharmaceuticals represent a powerful dual approach: they deliver targeted treatment directly to tumors while simultaneously providing the imaging tools needed to assess efficacy. The nukliD network is the bridge that connects this therapeutic promise with clinical reality—mobilizing available expertise and infrastructure in the Dresden region to catalyze meaningful progress for patients.
The Hi-Acts innovation platform, together with the Helmholtz-Zentrum Dresden-Rossendorf (HZDR), is driving the establishment of the nukliD network. The goal: to strengthen collaboration between science, medicine, and industry – and make the cancer therapy of tomorrow a reality.